lomustine has been researched along with Disease Exacerbation in 52 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme." | 9.09 | A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. ( Bruner, JM; Groves, MD; Hess, K; Jaeckle, KA; Kyritsis, AP; Levin, VA; Maor, MH; Meyers, C; Peterson, P; Sawaya, RE; Yung, WK, 1999) |
| "To conduct a Phase II one-arm study to evaluate the long-term efficacy and safety of accelerated fractionated radiotherapy combined with intravenous carboplatin for patients with previously untreated glioblastoma multiforme tumors." | 9.08 | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. ( Bruner, J; Kyritsis, AP; Leeds, N; Levin, VA; Maor, MH; Rodriguez, L; Sawaya, R; Thall, PF; Woo, S; Yung, WK, 1995) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "The aim of this study was to evaluate the toxicity, response, and survival of patients with relapsed high-grade gliomas after radiation therapy (RT) combined with lomustine (CCNU)." | 7.70 | Reirradiation and lomustine in patients with relapsed high-grade gliomas. ( Arcicasa, M; Bidoli, E; Dedkov, A; Gigante, M; Roncadin, M; Trovò, MG, 1999) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 7.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 6.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma." | 5.12 | PCV chemotherapy for recurrent glioblastoma. ( Dichgans, J; Dietz, K; Fischer, J; Herrlinger, U; Schmidt, F; Weller, M, 2006) |
| "The aim of this study was to compare tolerance of a nitrosurea-based regime with 'standard' therapy of vincristine (VCR) and carboplatin for low-grade gliomas." | 5.10 | Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas. ( Hoddes, JA; Lancaster, DL; Michalski, A, 2003) |
| "To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme." | 5.09 | A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. ( Bruner, JM; Groves, MD; Hess, K; Jaeckle, KA; Kyritsis, AP; Levin, VA; Maor, MH; Meyers, C; Peterson, P; Sawaya, RE; Yung, WK, 1999) |
| "To conduct a Phase II one-arm study to evaluate the long-term efficacy and safety of accelerated fractionated radiotherapy combined with intravenous carboplatin for patients with previously untreated glioblastoma multiforme tumors." | 5.08 | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. ( Bruner, J; Kyritsis, AP; Leeds, N; Levin, VA; Maor, MH; Rodriguez, L; Sawaya, R; Thall, PF; Woo, S; Yung, WK, 1995) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "The addition of procarbazine, lomustine, vincristine (PCV) chemotherapy to radiotherapy (RT) for patients with high-risk (≥40 y old or subtotally resected) low-grade glioma (LGG) results in an absolute median survival benefit of over 5 years." | 3.85 | Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma. ( Bendavid, E; Chang, DT; Chin, AL; Durkee, BY; Harris, JP; Kim, H; Kumar, KA; Maruyama, S; Owens, DK; Pitt, A; Pollom, EL; Qian, Y; Soltys, SG, 2017) |
| "We collected 6 case-reports of symptomatric non removable low grade fibrillary astrocytoma of adults treated with a procarbazine-CCNU-vincristine chemotherapy regimen." | 3.72 | [Neoadjuvant chemotherapy for symptomatic non operable grade II fibrillary astrocytoma in adults]. ( Alchaar, H; Bleuse, A; Bondiau, PY; Bourg, V; Brunetto, JL; Chanalet, S; Chatel, M; Courdi, A; Darcourt, J; Fauchon, F; Fontaine, D; Frénay, M; Grellier, P; Guibert, F; Lanteri-Minet, M; Lebrun, C; Lonjon, M; Michiels, JF; Paquis, P; Paquis, V; Ramaioli, A; Rasendrarijao, D; Vandenbos, F, 2004) |
| "The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy." | 3.71 | PCV chemotherapy for recurrent glioblastoma multiforme. ( Groeneveld, GJ; Heimans, JJ; Kappelle, AC; Postma, TJ; Sneeuw, KC; Taphoorn, MJ; van den Bent, MJ; van Groeningen, CJ; Zonnenberg, BA, 2001) |
| "The aim of this study was to evaluate the toxicity, response, and survival of patients with relapsed high-grade gliomas after radiation therapy (RT) combined with lomustine (CCNU)." | 3.70 | Reirradiation and lomustine in patients with relapsed high-grade gliomas. ( Arcicasa, M; Bidoli, E; Dedkov, A; Gigante, M; Roncadin, M; Trovò, MG, 1999) |
| "We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery." | 3.70 | Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 3.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Based on studies relating to anaplastic oligodendroglioma (OG) chemosensitivity and benefit of time to progression or overall survival, chemotherapy for pure OG has been proposed." | 2.73 | Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. ( Bourg, V; Chanalet, S; Fauchon, F; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Paquis, P; Ramaioli, A; Vandenbos, F, 2007) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 2.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "A median of two cycles were given until disease progression or grade 3/4 toxicity." | 2.71 | Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial. ( Neville, F; Nystrom, ML; Oliver, RT; Shamash, J; Steele, JP, 2003) |
| "Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity." | 2.71 | Initial chemotherapy in gliomatosis cerebri. ( Carpentier, A; Cartalat-Carel, S; Chinot, O; Cougnard, J; Delattre, JY; Djafari, L; Duffau, H; Gervais, H; Hoang-Xuan, K; Honnorat, J; Laigle, F; Mokhtari, K; Napolitano, M; Sanson, M; Taillandier, L; Taillibert, S, 2004) |
| "The outcome of a child with a primitive neuroectodermal tumors arising supratentorially (SPNET) is not well characterized and may differ from the outcome of a patient with a histologically similar cerebellar tumor (medulloblastoma [MB])." | 1.31 | Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. ( Janss, AJ; Packer, RJ; Phillips, PC; Reddy, AT; Weiss, HL, 2000) |
| "Several protocols for the adjuvant treatment of glioblastoma multiforme (GBM) are currently being evaluated." | 1.31 | Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo. ( Deininger, MH; Grote, E; Meyermann, R; Wickboldt, J, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (19.23) | 18.2507 |
| 2000's | 26 (50.00) | 29.6817 |
| 2010's | 14 (26.92) | 24.3611 |
| 2020's | 2 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Purzycka, K | 1 |
| Peters, LM | 1 |
| Desmas, I | 1 |
| Davies, O | 1 |
| Chang, YM | 1 |
| Lara-Garcia, A | 1 |
| Werner, JM | 1 |
| Weller, J | 1 |
| Ceccon, G | 2 |
| Schaub, C | 1 |
| Tscherpel, C | 2 |
| Lohmann, P | 2 |
| Bauer, EK | 2 |
| Schäfer, N | 2 |
| Stoffels, G | 2 |
| Baues, C | 1 |
| Celik, E | 1 |
| Marnitz, S | 1 |
| Kabbasch, C | 1 |
| Gielen, GH | 1 |
| Fink, GR | 2 |
| Langen, KJ | 3 |
| Herrlinger, U | 4 |
| Galldiks, N | 2 |
| Qian, Y | 1 |
| Maruyama, S | 1 |
| Kim, H | 1 |
| Pollom, EL | 1 |
| Kumar, KA | 1 |
| Chin, AL | 1 |
| Harris, JP | 1 |
| Chang, DT | 1 |
| Pitt, A | 1 |
| Bendavid, E | 1 |
| Owens, DK | 1 |
| Durkee, BY | 1 |
| Soltys, SG | 1 |
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 1 |
| Guo, J | 1 |
| Villano, JL | 1 |
| Dunkl, V | 1 |
| Law, I | 1 |
| Henriksen, OM | 1 |
| Muhic, A | 1 |
| Poulsen, HS | 1 |
| Steger, J | 1 |
| Schmidt, M | 1 |
| Shah, NJ | 1 |
| Cairncross, JG | 2 |
| Wang, M | 1 |
| Jenkins, RB | 2 |
| Shaw, EG | 1 |
| Giannini, C | 1 |
| Brachman, DG | 1 |
| Buckner, JC | 2 |
| Fink, KL | 1 |
| Souhami, L | 1 |
| Laperriere, NJ | 1 |
| Huse, JT | 1 |
| Mehta, MP | 1 |
| Curran, WJ | 2 |
| Tonder, M | 1 |
| Eisele, G | 1 |
| Weiss, T | 1 |
| Hofer, S | 1 |
| Seystahl, K | 1 |
| Valavanis, A | 1 |
| Stupp, R | 1 |
| Weller, M | 4 |
| Roth, P | 1 |
| Taal, W | 1 |
| van der Rijt, CC | 2 |
| Dinjens, WN | 1 |
| Sillevis Smitt, PA | 3 |
| Wertenbroek, AA | 1 |
| Bromberg, JE | 1 |
| van Heuvel, I | 1 |
| Kros, JM | 3 |
| van den Bent, MJ | 5 |
| Schiff, D | 2 |
| Kaloshi, G | 1 |
| Roci, E | 1 |
| Rroji, A | 1 |
| Ducray, F | 2 |
| Petrela, M | 1 |
| Nicolin, G | 1 |
| Parkin, P | 1 |
| Mabbott, D | 1 |
| Hargrave, D | 1 |
| Bartels, U | 1 |
| Tabori, U | 1 |
| Rutka, J | 1 |
| Buncic, JR | 1 |
| Bouffet, E | 1 |
| Proctor, SJ | 1 |
| Lennard, AL | 1 |
| Jackson, GH | 1 |
| Jones, GL | 1 |
| Lewis, J | 1 |
| Wilkinson, J | 1 |
| White, J | 1 |
| Sieniawski, M | 1 |
| McKay, P | 1 |
| Culligan, D | 1 |
| Lucraft, HH | 1 |
| Wick, W | 1 |
| Hartmann, C | 1 |
| Engel, C | 1 |
| Stoffels, M | 1 |
| Felsberg, J | 2 |
| Stockhammer, F | 1 |
| Sabel, MC | 1 |
| Koeppen, S | 1 |
| Ketter, R | 1 |
| Meyermann, R | 2 |
| Rapp, M | 1 |
| Meisner, C | 1 |
| Kortmann, RD | 1 |
| Pietsch, T | 2 |
| Wiestler, OD | 1 |
| Ernemann, U | 1 |
| Bamberg, M | 2 |
| Reifenberger, G | 2 |
| von Deimling, A | 1 |
| Mishra, KK | 1 |
| Squire, S | 1 |
| Lamborn, K | 2 |
| Banerjee, A | 1 |
| Gupta, N | 1 |
| Wara, WM | 1 |
| Prados, MD | 3 |
| Berger, MS | 1 |
| Haas-Kogan, DA | 1 |
| Lassman, AB | 1 |
| Iwamoto, FM | 1 |
| Cloughesy, TF | 1 |
| Aldape, KD | 1 |
| Rivera, AL | 1 |
| Eichler, AF | 1 |
| Louis, DN | 1 |
| Paleologos, NA | 1 |
| Fisher, BJ | 1 |
| Ashby, LS | 1 |
| Roldán, GB | 1 |
| Wen, PY | 1 |
| Ligon, KL | 1 |
| Robins, HI | 1 |
| Rocque, BG | 1 |
| Chamberlain, MC | 2 |
| Mason, WP | 1 |
| Weaver, SA | 1 |
| Green, RM | 1 |
| Kamar, FG | 1 |
| Abrey, LE | 1 |
| DeAngelis, LM | 1 |
| Jhanwar, SC | 1 |
| Rosenblum, MK | 1 |
| Panageas, KS | 1 |
| Glas, M | 2 |
| Bähr, O | 1 |
| Rasch, K | 1 |
| Wiewrodt, D | 1 |
| Schabet, M | 1 |
| Simon, M | 2 |
| Urbach, H | 2 |
| Steinbach, JP | 1 |
| Rieger, J | 1 |
| Fimmers, R | 1 |
| Nägele, T | 1 |
| Stuplich, M | 1 |
| Hadizadeh, DR | 1 |
| Kuchelmeister, K | 1 |
| Scorzin, J | 1 |
| Filss, C | 1 |
| Mack, F | 1 |
| Schüller, H | 1 |
| Piribauer, M | 1 |
| Fazeny-Dörner, B | 1 |
| Rössler, K | 1 |
| Ungersböck, K | 1 |
| Czech, T | 1 |
| Killer, M | 1 |
| Dieckmann, K | 1 |
| Birner, P | 1 |
| Prayer, D | 1 |
| Hainfellner, J | 1 |
| Muhm, M | 1 |
| Marosi, C | 2 |
| Looijenga, LH | 1 |
| Langenberg, K | 1 |
| Dinjens, W | 1 |
| Graveland, W | 1 |
| Uytdewilligen, L | 1 |
| Chinot, O | 2 |
| Boogerd, W | 1 |
| Bravo Marques, J | 1 |
| Taphoorn, MJ | 2 |
| Vecht, CJ | 1 |
| De Beule, N | 1 |
| Baron, B | 1 |
| Nystrom, ML | 1 |
| Steele, JP | 1 |
| Shamash, J | 1 |
| Neville, F | 1 |
| Oliver, RT | 1 |
| Sunyach, MP | 1 |
| Pommier, P | 1 |
| Martel Lafay, I | 1 |
| Guyotat, J | 1 |
| Ginestet, G | 1 |
| Jouanneau, E | 1 |
| Jouvet, A | 1 |
| Sindou, M | 1 |
| Bret, P | 1 |
| Carrie, C | 1 |
| Frappaz, D | 1 |
| Lancaster, DL | 1 |
| Hoddes, JA | 1 |
| Michalski, A | 1 |
| Lebrun, C | 2 |
| Fontaine, D | 2 |
| Vandenbos, F | 2 |
| Chanalet, S | 2 |
| Bourg, V | 2 |
| Frénay, M | 2 |
| Alchaar, H | 1 |
| Bleuse, A | 1 |
| Bondiau, PY | 1 |
| Brunetto, JL | 1 |
| Chatel, M | 1 |
| Courdi, A | 1 |
| Darcourt, J | 1 |
| Fauchon, F | 2 |
| Guibert, F | 1 |
| Grellier, P | 1 |
| Lanteri-Minet, M | 1 |
| Lonjon, M | 2 |
| Michiels, JF | 1 |
| Paquis, P | 2 |
| Paquis, V | 1 |
| Ramaioli, A | 2 |
| Rasendrarijao, D | 1 |
| Sanson, M | 1 |
| Cartalat-Carel, S | 1 |
| Taillibert, S | 1 |
| Napolitano, M | 1 |
| Djafari, L | 1 |
| Cougnard, J | 1 |
| Gervais, H | 1 |
| Laigle, F | 1 |
| Carpentier, A | 1 |
| Mokhtari, K | 1 |
| Taillandier, L | 1 |
| Duffau, H | 1 |
| Honnorat, J | 1 |
| Hoang-Xuan, K | 1 |
| Delattre, JY | 1 |
| de Wit, MC | 1 |
| de Bruin, HG | 1 |
| Eijkenboom, W | 1 |
| Schmidt, F | 1 |
| Fischer, J | 1 |
| Dietz, K | 1 |
| Dichgans, J | 1 |
| Faber, V | 1 |
| Thödtmann, R | 1 |
| Piccirilli, M | 1 |
| Landi, A | 1 |
| Salvati, M | 1 |
| Walker, C | 1 |
| Haylock, B | 1 |
| Husband, D | 1 |
| Joyce, KA | 1 |
| Fildes, D | 1 |
| Jenkinson, MD | 1 |
| Smith, T | 1 |
| Broome, J | 1 |
| Kopitzki, K | 1 |
| du Plessis, DG | 1 |
| Prosser, J | 1 |
| Vinjamuri, S | 1 |
| Warnke, PC | 1 |
| Rusk, A | 1 |
| Cozzi, E | 1 |
| Stebbins, M | 1 |
| Vail, D | 1 |
| Graham, J | 1 |
| Valli, V | 1 |
| Henkin, J | 1 |
| Sharpee, R | 1 |
| Khanna, C | 1 |
| Yang, SH | 1 |
| Hong, YK | 1 |
| Yoon, SC | 1 |
| Kim, BS | 1 |
| Lee, YS | 1 |
| Lee, TK | 1 |
| Lee, KS | 1 |
| Jeun, SS | 1 |
| Kim, MC | 1 |
| Park, CK | 1 |
| Gill, P | 1 |
| Litzow, M | 1 |
| Buckner, J | 1 |
| Arndt, C | 1 |
| Moynihan, T | 1 |
| Christianson, T | 1 |
| Ansell, S | 1 |
| Galanis, E | 1 |
| Levin, VA | 5 |
| Maor, MH | 2 |
| Thall, PF | 1 |
| Yung, WK | 4 |
| Bruner, J | 2 |
| Sawaya, R | 1 |
| Kyritsis, AP | 4 |
| Leeds, N | 1 |
| Woo, S | 1 |
| Rodriguez, L | 1 |
| Jakacki, RI | 1 |
| Zeltzer, PM | 1 |
| Boyett, JM | 1 |
| Albright, AL | 1 |
| Allen, JC | 1 |
| Geyer, JR | 1 |
| Rorke, LB | 1 |
| Stanley, P | 1 |
| Stevens, KR | 1 |
| Wisoff, J | 1 |
| Jaeckle, KA | 3 |
| Gleason, MJ | 1 |
| Ictech, SE | 1 |
| Flowers, A | 1 |
| Edwards, MS | 1 |
| Rabbitt, J | 1 |
| Davis, RL | 1 |
| Kaba, SE | 1 |
| Hess, K | 2 |
| Mercier, R | 1 |
| Dakhil, S | 1 |
| Urban, C | 1 |
| Benesch, M | 1 |
| Pakisch, B | 1 |
| Lackner, H | 1 |
| Kerbl, R | 1 |
| Schwinger, W | 1 |
| Oberbauer, R | 1 |
| Arcicasa, M | 1 |
| Roncadin, M | 1 |
| Bidoli, E | 1 |
| Dedkov, A | 1 |
| Gigante, M | 1 |
| Trovò, MG | 1 |
| Groves, MD | 1 |
| Meyers, C | 1 |
| Sawaya, RE | 1 |
| Bruner, JM | 1 |
| Peterson, P | 1 |
| Scott, C | 1 |
| Sandler, H | 1 |
| Phillips, T | 1 |
| Schultz, C | 1 |
| Urtasun, R | 1 |
| Davis, R | 1 |
| Gutin, P | 1 |
| Cascino, TL | 1 |
| Greenberg, HS | 1 |
| Reddy, AT | 1 |
| Janss, AJ | 1 |
| Phillips, PC | 1 |
| Weiss, HL | 1 |
| Packer, RJ | 1 |
| Boiardi, A | 2 |
| Eoli, M | 1 |
| Pozzi, A | 1 |
| Salmaggi, A | 1 |
| Broggi, G | 1 |
| Silvani, A | 1 |
| Deininger, MH | 1 |
| Grote, E | 1 |
| Wickboldt, J | 1 |
| Kappelle, AC | 1 |
| Postma, TJ | 1 |
| Groeneveld, GJ | 1 |
| van Groeningen, CJ | 1 |
| Zonnenberg, BA | 1 |
| Sneeuw, KC | 1 |
| Heimans, JJ | 1 |
| Cairncross, G | 1 |
| Swinnen, L | 1 |
| Bayer, R | 1 |
| Rosenfeld, S | 1 |
| Salzman, D | 1 |
| Paleologos, N | 1 |
| Kaminer, L | 1 |
| Forsyth, P | 1 |
| Stewart, D | 1 |
| Peterson, K | 1 |
| Hu, W | 1 |
| Macdonald, D | 1 |
| Ramsay, D | 1 |
| Smith, A | 1 |
| Croteau, D | 1 |
| Mikkelsen, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy[NCT00003304] | Phase 2 | 29 participants (Anticipated) | Interventional | 1998-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for lomustine and Disease Exacerbation
| Article | Year |
|---|---|
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Disease Progress | 2010 |
Chemotherapy for diffuse low-grade gliomas in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chemother | 2011 |
Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Damage, Chronic; Brain Injuries | 2003 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Adults with newly diagnosed high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2001 |
21 trials available for lomustine and Disease Exacerbation
| Article | Year |
|---|---|
Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
Topics: Adult; Aged; Bevacizumab; Disease Progression; Drug Interactions; Female; Glioblastoma; Humans; Lomu | 2018 |
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chi-Square Distr | 2014 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Di | 2010 |
NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2011 |
Feasibility and toxicity of CCNU therapy in elderly patients with glioblastoma multiforme.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; Fe | 2003 |
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylatin | 2003 |
Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Chi | 2003 |
Initial chemotherapy in gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
PCV chemotherapy for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; D | 2006 |
Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Disease Progressio | 2006 |
Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Disease | 2007 |
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemother | 1995 |
Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: a report of the Childrens Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 1995 |
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1997 |
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1997 |
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Che | 1998 |
A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain | 1999 |
A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bromodeoxyuridine; Che | 1999 |
25 other studies available for lomustine and Disease Exacerbation
| Article | Year |
|---|---|
Clinicopathological characteristics and prognostic factors for canine multicentric non-indolent T-cell lymphoma: 107 cases.
Topics: Animals; Antineoplastic Agents, Alkylating; Disease Progression; Dog Diseases; Dogs; Lomustine; Lymp | 2020 |
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2021 |
Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cost-Bene | 2017 |
Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Drug Therapy, Combination; Femal | 2015 |
Kinetic evaluation of low-grade gliomas in adults before and after treatment with CCNU alone.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2015 |
Natural history and outcome of optic pathway gliomas in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Damage, Chronic; Carboplatin; Chil | 2009 |
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chr | 2011 |
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosome Aberrations; Chromosomes | 2003 |
[Neoadjuvant chemotherapy for symptomatic non operable grade II fibrillary astrocytoma in adults].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Astrocytom | 2004 |
Gliomatosis cerebri: better definition, better treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocyt | 2004 |
[Palliative therapy in glioblastoma multiforme: a multimodal concept].
Topics: Aged; Brain Neoplasms; Catheters, Indwelling; Chemotherapy, Adjuvant; Combined Modality Therapy; Cra | 2006 |
Gliomatosis cerebri treatment in 11 elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2006 |
Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes, | 2006 |
Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2007 |
High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 2008 |
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr | 1996 |
Reirradiation and lomustine in patients with relapsed high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease | 1999 |
Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytoge | 2000 |
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy | 1999 |
Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apop | 2000 |
PCV chemotherapy for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Glioblasto | 2001 |
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta | 2000 |
PCV chemotherapy for recurrent glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Female; Gliobl | 2001 |